Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 1Leukemia, Plasma Cell 1Adenoma, Islet Cell 1

Interventions

fludarabine phosphate 2fludarabine 2Lenalidomide 2Cyclophosphamide 2sargramostim 1plerixafor 1pegylated granulocyte colony-stimulating factor 1montanide ISA 51 1incomplete Freund's adjuvant 1ferric pyrophosphate 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1carfilzomib 1auricularum 1Whole-Body Irradiation 1Stem Cell Transplantation 1Specimen Handling 1Melphalan 1Magnetic Resonance Spectroscopy 1Hyaluronoglucosaminidase 1High-Throughput Screening Assays 1Fluorodeoxyglucose F18 1Dexamethasone 1Cyclosporine 1Colony-Stimulating Factors 1Calcium Dobesilate 1Budesonide 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Plasma Cell × incomplete Freund's adjuvant × 90 days × Clear all
NCT02334865 2026-05-15

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Roswell Park Cancer Institute

Phase 1 Active not recruiting
18 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡